167. マルファン症候群 ［臨床試験数：14，薬物数：28（DrugBank：10），標的遺伝子数：10，標的パスウェイ数：45］
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023612-14-GB | 08/03/2013 | 18 March 2013 | The Oxford Marfan Trial | A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 | Marfan syndrome. MedDRA version: 14.1 Level: PT Classification code 10026829 Term: Marfan's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Aprovel Product Name: Aprovel Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Irbesartan CAS Number: 38402-11-6 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 150-300 Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Vibrox 100mg Capsules Product Name: Vibrox Pharmaceutical Form: Capsule INN or Proposed INN: Doxycycline Hyclate Ph.Eur CAS Number: 564-25-0 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 100-200 Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Clinical Trials and Research Governance | Authorised | Female: yes Male: yes | United Kingdom | |||||
| 2 | EUCTR2010-019302-16-GB | 13/09/2010 | 28 February 2019 | A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome | A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome - The AIMS Study | Marfan Syndrome | Trade Name: Aprovel Product Name: Aprovel Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Royal Brompton and Harefield NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 490 | Phase 3 | United Kingdom | |||
| 3 | NCT01715207 | June 2010 | 16 December 2017 | Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS | Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol | Marfan Syndrome | Drug: Aliskiren;Drug: Atenolol | Samsung Medical Center | Not recruiting | 14 Years | 55 Years | All | 30 | Phase 3 | Korea, Republic of | |
| 4 | NCT00782327 | June 2009 | 29 June 2015 | Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers | Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers | Marfan Syndrome | Drug: Losartan;Drug: Placebo | University Hospital, Ghent | Agentschap voor Innovatie door Wetenschap en Technologie | Recruiting | 10 Years | N/A | Both | 174 | Phase 3 | Belgium |
| 5 | EUCTR2007-005862-10-BE | 29/05/2009 | 10 July 2015 | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Marfan syndrome MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome | Trade Name: Cozaar Product Name: Losartan Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Coozar Product Name: Losartan Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Coozar Product Name: Losartan Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | University Hospital Ghent | Not Recruiting | Female: yes Male: yes | Belgium | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2008-001462-81-IT | 27/10/2008 | 9 May 2016 | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Marfan Syndrome MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome | Trade Name: LORTAAN*28CPR RIV DIV 50MG Pharmaceutical Form: Coated tablet INN or Proposed INN: Losartan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: LOBIVON*28CPR 5MG Pharmaceutical Form: Tablet INN or Proposed INN: Nebivolol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | OSPEDALE POLICLINICO S. MATTEO | Not Recruiting | Female: yes Male: yes | Phase 3 | Italy | ||||
| 7 | EUCTR2007-001125-97-ES | 20/05/2008 | 19 March 2012 | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome | Trade Name: cozaar 50 Pharmaceutical Form: Capsule* INN or Proposed INN: LOSARTAN POTASSIUM CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: blokium 50 Pharmaceutical Form: Capsule* INN or Proposed INN: ATENOLOL CAS Number: 29122687 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula Pharmaceutical Form: Capsule* INN or Proposed INN: LOSARTAN POTASSIUM CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: BLOKIUM 50 mg comprimidos Pharmaceutical Form: Capsule* INN or Proposed INN: ATENOLOL CAS Number: 29122687 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | alberto forteza | Authorised | Female: yes Male: yes | Spain | |||||
| 8 | NCT00593710 | January 2008 | 19 February 2015 | Losartan Versus Atenolol for the Treatment of Marfan Syndrome | A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan;Drug: Atenolol | University of British Columbia | Heart and Stroke Foundation of Canada | Not recruiting | 12 Years | 25 Years | Both | 17 | Phase 2 | Canada |
| 9 | NCT00723801 | October 2007 | 19 October 2017 | Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome | Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome | Marfan Syndrome | Drug: Atenolol;Drug: Losartan | Brigham and Women's Hospital | Boston Children’s Hospital | Not recruiting | 25 Years | N/A | All | 40 | Phase 3 | United States |
| 10 | NCT00651235 | February 2007 | 19 February 2015 | A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan and Atenolol or Propranolol;Drug: Atenolol or Propranolol | National Taiwan University Hospital | Recruiting | 1 Year | N/A | Both | 44 | Phase 2 | Taiwan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00429364 | January 2007 | 19 October 2017 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) | Marfan Syndrome | Drug: Losartan Potassium;Drug: Atenolol | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan Foundation | Not recruiting | 6 Months | 25 Years | All | 608 | Phase 3 | United States;Belgium;Canada |
| 12 | EUCTR2006-003991-37-BE | 13/12/2006 | 11 April 2016 | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Marfan syndrome MedDRA version: 8.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome | Product Name: losartan Pharmaceutical Form: Tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Product Name: losartan Pharmaceutical Form: Tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: losartan Pharmaceutical Form: Tablet INN or Proposed INN: Losartan potassium CAS Number: 124750998 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Atenolol Pharmaceutical Form: Tablet INN or Proposed INN: Atenolol CAS Number: 29122687 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: Atenolol Pharmaceutical Form: Tablet INN or Proposed INN: Atenolol CAS Number: 29122687 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Atenolol Pharmaceutical Form: Tablet INN or Proposed INN: Atenolol CAS Number: 29122687 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | University Hospital Gent | Not Recruiting | Female: yes Male: yes | 600 | Belgium | ||||
| 13 | EUCTR2005-000749-13-GB | 30/07/2005 | 24 April 2012 | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | Marfan Syndrome | Trade Name: Atenolol Product Name: Atenolol Product Code: N/A Pharmaceutical Form: Capsule* INN or Proposed INN: N/A CAS Number: -29122-68-7 Current Sponsor code: CO7AB03 Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75 MG ONCE DAILY- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Coversyl Product Name: Coversyl Product Code: N/A Pharmaceutical Form: Capsule* INN or Proposed INN: N/A CAS Number: -95153-31-4 Current Sponsor code: CO9AA04 Other descriptive name: PERINDOPRIL Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4MG ONCE DAILY Route of administration of the placebo: Oral use Trade Name: Verapamil Product Code: N/A Pharmaceutical Form: Capsule* INN or Proposed INN: N/A CAS Number: -152-11-4 Current Sponsor code: CO8DA01 Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 240 MG ONCE DAILY- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Cardiff University | Authorised | Female: yes Male: yes | 60 | United Kingdom | ||||
| 14 | NCT00485368 | January 2004 | 19 February 2015 | Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome | The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Coversyl (perindopril) | Bayside Health | Baker Heart Research Institute;The Alfred | Not recruiting | 18 Years | 40 Years | Both | 17 | Phase 3 |